Evidence map›Paper›PMID 34995084›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).

En Cheng, Fang-Shu Ou, Chao Ma, Donna Spiegelman, Sui Zhang, Xin Zhou, Tiffany M Bainter, Leonard B Saltz, Donna Niedzwiecki, Robert J Mayer and 13 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06314958 (Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06314958 recruitingnot on this mapstarted 2023, after this paper: background citation

Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment

TypeobservationalSponsorCity of Hope Medical CenterRan2023 to 2028Enrolled400ConditionsColorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage IIIArmsCENSURE
3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prevalence and Cancer-Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. International journal of general medicine · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Nutritional Treatment of Patients with Colorectal Cancer.International journal of environmental research and public health · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

En ChengDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.ORCID 0000-0001-9523-9310
Fang-Shu OuAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.ORCID 0000-0003-1267-8735
Chao MaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7741-818X
Donna SpiegelmanDepartment of Biostatistics, Yale School of Public Health, New Haven, CT.ORCID 0000-0003-4006-4650
Sui ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-8279-6353
Xin ZhouDepartment of Biostatistics, Yale School of Public Health, New Haven, CT.ORCID 0000-0003-2238-2890
Tiffany M BainterAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
Leonard B SaltzMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-8353-4670
Donna NiedzwieckiDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC.ORCID 0000-0002-3566-0450
Robert J MayerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Renaud WhittomHôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
Alexander HantelLoyola University, Stritch School of Medicine, Naperville, IL.
Al BensonRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.ORCID 0000-0001-5485-7227
Daniel AtienzaVirginia Oncology Associates, Norfolk, VA.
Michael MessinoMessino Cancer Centers, Asheville, NC.
Hedy KindlerUniversity of Chicago, Chicago, IL.ORCID 0000-0002-5450-842X
Edward L GiovannucciDepartment of Epidemiology, and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-6123-0219
Erin L Van BlariganDepartment of Epidemiology and Biostatistics, and Urology, University of California, San Francisco, CA.ORCID 0000-0001-5079-3385
Justin C BrownCancer Metabolism Program, Pennington Biomedical Research Center, Baton Rouge, LA.ORCID 0000-0001-7540-4913
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-0631-1494
Cary P GrossDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Charles S FuchsDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.ORCID 0000-0003-1582-9842

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA197077NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA205406NCI NIH HHS R33 CA160344NCI NIH HHS T32 CA250803NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233327NCI NIH HHS UG1 CA233337
6 · The paper itself

Abstract

purposeCurrent tools in predicting survival outcomes for patients with colon cancer predominantly rely on clinical and pathologic characteristics, but increasing evidence suggests that diet and lifestyle habits are associated with patient outcomes and should be considered to enhance model accuracy.

methodsUsing an adjuvant chemotherapy trial for stage III colon cancer (CALGB 89803), we developed prediction models of disease-free survival (DFS) and overall survival by additionally incorporating self-reported nine diet and lifestyle factors. Both models were assessed by multivariable Cox proportional hazards regression and externally validated using another trial for stage III colon cancer (CALGB/SWOG 80702), and visual nomograms of prediction models were constructed accordingly. We also proposed three hypothetical scenarios for patients with (1) good-risk, (2) average-risk, and (3) poor-risk clinical and pathologic features, and estimated their predictive survival by considering clinical and pathologic features with or without adding self-reported diet and lifestyle factors.

resultsAmong 1,024 patients (median age 60.0 years, 43.8% female), we observed 394 DFS events and 311 deaths after median follow-up of 7.3 years. Adding self-reported diet and lifestyle factors to clinical and pathologic characteristics meaningfully improved performance of prediction models (c-index from 0.64 [95% CI, 0.62 to 0.67] to 0.69 [95% CI, 0.67 to 0.72] for DFS, and from 0.67 [95% CI, 0.64 to 0.70] to 0.71 [95% CI, 0.69 to 0.75] for overall survival). External validation also indicated good performance of discrimination and calibration. Adding most self-reported favorable diet and lifestyle exposures to multivariate modeling improved 5-year DFS of all patients and by 6.3% for good-risk, 21.4% for average-risk, and 42.6% for poor-risk clinical and pathologic features.

conclusionDiet and lifestyle factors further inform current recurrence and survival prediction models for patients with stage III colon cancer.

Indexed as

DietLife StyleModels, StatisticalNomogramsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsFemaleFollow-Up StudiesHumansMaleMiddle AgedMulticenter Studies as TopicNeoplasm Recurrence, LocalPrognosis

Identifiers

PMID34995084
PMCPMC8887946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.